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Abstract
Purpose: To evaluate the effectiveness of platelet rich plasma (PRP) in musculoskeletal
pathologies.
Methods: We completed a review of the literature on the use of PRP in tendon, muscle,
bone, and intra-articular pathologies (Chapter 2). We completed a systematic review and
meta-analysis on the effectiveness of PRP in ultrasound guided versus palpation guided
injections of PRP in non-operative treatment of tendon and muscle pathologies using an
indirect analysis method (Chapter 3). We conducted a randomized controlled trial to
determine the effectiveness of PRP versus corticosteroid (CS) injections in patients with
plantar fasciitis (Chapter 4).
Results: Most studies evaluating the effectiveness of PRP in musculoskeletal pathologies are for
the treatment of tendon and intra-articular pathologies, with fewer studies assessing its
effectiveness in muscle and bone healing. The published studies included in the review had a
heterogenous summation of results that could not be used to conclusively determine the
superiority of PRP over other treatments for musculoskeletal pathologies. We included 26
studies in our systematic review to compare ultrasound versus palpation guided injections of
PRP. We found no statistically significant difference between ultrasound versus palpation guided
injections for failure rates and pain outcomes at two months, two to three months, and six months
following injection (p > 0.05). The comparison of functional outcomes at six months showed a
significant effect in favor of palpation guided injections (p = 0.01), but heterogeneity of the
analysis was high (I2 = 83.5%) and we were unable to make any definitive conclusions on the
results. In our RCT, we found no statistically significant difference between PRP versus CS
injections for our primary outcome of pain and function using the American Orthopaedic Foot
and Ankle Society Ankle-hindfoot scale, at six months or one year. We also found no
statistically significant difference for all other outcomes at six months and one year.
Conclusion: The results in all three of our studies do not provide supporting evidence for the
superior effectiveness of PRP injections in musculoskeletal pathologies. There are currently no
ii

clear indications for the clinical use of PRP injections in musculoskeletal pathologies and further
research is needed in this area.
Keywords: Platelet rich plasma, musculoskeletal pathologies, ultrasound guided injections,
palpation guided injections, tendon, muscle, bone, intra-articular, ligament, plantar fasciitis,
corticosteroid injections
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Chapter 1 Introduction
The overall purpose of this thesis was to evaluate the effectiveness of platelet rich plasma (PRP)
as a treatment for musculoskeletal pathologies. PRP was introduced in the late 1990’s in the oral
and maxillofacial field but the demand for PRP in sports medicine took off in 2009, largely
fueled by the media when Hines Ward and Troy Polamalu of the Pittsburgh Stealers used PRP
for their sports pathologies prior to the team winning the NFL Superbowl. Since then the
number of published studies has grown.
PRP is a concentrated volume of human platelets suspended in plasma66. PRP is obtained when
whole blood from an individual is spun in a centrifuge to separate the blood into its components
(plasma, leukocytes, platelets and red blood cells) before drawing the plasma, platelets (and
potentially leukocytes) from the solution and injecting it into the injury site. The theory behind
the effectiveness of PRP is that the elevated concentration of growth-factor-releasing platelets
will improve tissue healing.
Platelets release growth factors that are responsible for the anabolic (tissue building) processes
involved in tissue healing. The most common growth factors found in PRP include plateletderived epidermal growth factor (PD-EGF), platelet-derived growth factor (PDGF) A and B,
transforming growth factor (TGF-β1), insulin-like growth factor (IGF-I, II), vascular endothelial
growth factor (VEGF), endothelial cell growth factor (ECGF), and basic fibroblast growth factor
(bFGF)28.
The concentration of platelets found in PRP compared to whole blood varies between each
system and by individual; from being similar to the concentration found at time of blood draw to
up to 8 times the concentration. With differences in platelet concentration it makes sense that
there is also a variation in the concentration of growth factors and other bioactive components
responsible for tissue healing. It is important to note however, that a positive association
between increased platelet count and the concentration of growth factors present in a PRP
solution remains unproven as does the association between concentration and healing.
Platelets are activated and begin secretion of the growth factors when the clotting mechanism of
blood begins. The secretion of the growth factors naturally begins within 10 minutes of clotting,
and 95% of the growth factors are released within 1 hour of activation67. Some systems

2

encourage the use of activators such as thrombin, to activate the platelets and begin the secretion
of growth factors upon application of the PRP solution to the injured area. Others rely on the
natural clotting mechanism for the activation process of the platelets13,24,69,109. Most systems also
promote the addition of an anticoagulant, preferably anticoagulant citrate dextrose solution A
(ACD-A) or sodium citrate13, to prevent early clotting and enhance growth factor function.
The consensus of the ideal speed, force, and spin procedure (i.e. single versus double spin) for
centrifugation continues to be debated and more research is needed to compare the clinical
effectiveness of the solutions produced by each to conclusively determine superior effectiveness
amongst preparation systems.
In summary, the volume of good quality evidence in support of PRP is small and diluted by the
heterogeneity amongst studies caused by differences in the composition of PRP. Specifically,
there are a number of commercial systems available from industry and each system has a unique
protocol for the preparation and administration of the PRP solution to the injured tissue
(Appendix 1). Variations include the amount of blood drawn, whether to add an anticoagulant,
the spin time and speed of the centrifuge, whether to add an activator, and whether the resultant
PRP solution should include leukocytes
The thesis consists of three chapters. Our first chapter is a published systematized review of the
literature37 evaluating the effectiveness of PRP in muscle, tendon, cartilage, bone and intraarticular applications for musculoskeletal pathologies in humans (permission in Appendix 2) .
We also summarized the results of systematic reviews comparing studies that evaluate the use of
PRP in orthopaedic bone and soft tissue pathologies, and in arthroscopic rotator cuff repair.
Next, because some have argued that the effectiveness of PRP in musculoskeletal pathologies
may be hindered by the inaccurate injection of the treatment into the target tissue31,110, our
second chapter is a systematic review and meta-analysis to compare the effectiveness of
ultrasound-guided versus palpation alone when performing PRP injections in tendon and muscle
pathologies.
Finally, because the methodological strength of the published literature is weak, we designed and
implemented a methodologically rigorous randomized controlled trial (RCT) to compare the
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effectiveness of PRP versus corticosteroid injections in patients with plantar fasciitis.
Specifically, we built in methods to increase our certainty about our conclusions and reduce the
potential for bias including increasing the sample size, randomization, blinding of patients and
outcome assessors, stratification by symptom duration, and performing an adjusted analysis to
control for differences in pre-intervention health status and characteristics.
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Chapter 2 The Use of Platelet-rich Plasma in Orthopedic
Pathologies

Abstract
Platelet-rich plasma (PRP) is an autologous concentration of blood-derived human platelets in a
small volume of plasma. The types of PRP vary according to the commercial preparation system
used, the platelet concentration, or the anticoagulant or activator used. Autologous conditioned
plasma is an autologous concentration of human platelets in plasma 2 to 4 times greater than that
which is found in blood at baseline. Platelets are important to the normal healing response of
tissue by the local secretion of growth factors and recruitment of reparative cells in an area of
injury. PRP is theorized to create an optimal healing environment in a region of tissue injury.
This was a literature review of currently published studies using PRP in orthopedic pathologies.
We performed a literature search in PubMed and Medline in April 2013. We concluded that
given the number of variations of PRP available and the lack of high-level published studies,
there was insufficient evidence to conclusively support its clinical use.
Key Words: autologous conditioned plasma, platelet-rich plasma, orthopedic pathologies, sports
medicine, growth factors, tissue healing.

Introduction
Platelet-rich plasma (PRP) is an autologous concentration of blood-derived human platelets in a
small volume of plasma. Platelets are recognized as the major sources of growth factors and
proteins associated with tissue healing within blood clots and are involved in tissue regeneration
through the recruitment, proliferation, and differentiation of cells. The theoretical concept that
concentrating platelets at the injured site could accelerate and optimize the healing mechanisms
set the rationale for the development and continued research into the use of PRP in the clinical
application for orthopedic pathologies. PRP is a general term for this type of solution and
includes autologous conditioned plasma, platelet-enriched plasma, platelet-rich concentrate,
autogenous platelet gel, platelet releasate, platelet rich in growth factors, and others1–3. These
vary depending on the commercial preparation system, the platelet concentration, the
anticoagulant or activator used, or whether the resultant PRP contains leukocytes4,5. The most
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commonly used term in the literature is PRP. For this reason (and for simplicity) we will use the
term PRP throughout this review to refer to the general category of solutions that result in an
elevated concentration of platelets within a sample of plasma.

What are Platelets?
Platelets are a type of white blood cell derived from the fragmentation of precursor
megakarocytes and formed in the marrow3,6,7. They are the smallest of the blood cells, measuring
approximately 2 µm in diameter. Platelets contain more than 30 bioactive proteins including
some of the key growth factors, many of which have a fundamental role in the early stages of
tissue healing3,4. Commonly found elements which are crucial to the role of tissue healing
include platelet-derived growth factor AB, transforming growth factor b-1, and vascular
endothelial growth factor. Plasma is the fluid content of blood and contains clotting factors and
other proteins and ions8. The effect of PRP on tissue healing is a function of many variables,
including platelet concentration, the volume of PRP delivered, the extent and type of pathology,
and the overall medical condition of the patient4,9,10. Debate continues regarding the optimal
quantity of platelets and growth factors required for soft tissue and bone healing11-16. A
concentration 4 or more times that of whole blood has also been proposed11 but lower
concentrations of 2 to 3 times that of baseline blood has also been shown to be effective in cell
culture studies 12,13. Since the 1990s, PRP has been used in an array of fields including maxillafacial surgery11,14 and plastic surgery15,16. A growing body of laboratory evidence supports the
use of PRP injections for the treatment of muscle and tendon pathologies and degeneration17–20.
In vitro and in vivo studies suggest that growth factors released by platelets recruit reparative
cells and may augment soft-tissue repair20,21. Another advantage of platelet-rich therapies is the
antibactericidal effects of the antibacterial and fungicidal proteins stored in platelets, which may
help to prevent infection22,23.

Preparation and Delivery of PRP
There is considerable variation in the preparation of PRP. However, most processes include
taking a sample of autologous blood and adding a form of citrate as an anticoagulant which is
added before centrifugation of the blood6. The anticoagulants most commonly used are

8

anticoagulant citrate dextrose-A and citrate phosphate dextrose. These anticoagulants support the
metabolic needs of platelets and the viable separation of platelets in an undamaged manner3,24,25.
Some systems do not require the use of an anticoagulant especially if the PRP is administered
before clotting has been initiated26. The autologous blood is spun using a centrifuge, filter, or
separation system to separate the red blood cells from the leukocytes and platelets27. The
resultant is a visibly layered solution of red blood cells on the bottom, a thin milky-white layer of
leukocytes in the middle, and a yellow-tinged upper portion of PRP. The efficiency of red blood
cell separation and platelet concentration is dependent on the preparation system used, but all
PRP preparations contain the non-cellular components of plasma, including clotting factors27.
PRP can be administered with or without an activating agent, such as bovine thrombin, at the
time of delivery into the area of injury28. Both leukocyte-poor and leukocyte-rich preparations
have been used29–31.

Review of the Literature
Animal studies have been used to show the effectiveness of PRP on soft-tissue and bone healing
as the physiology is generally known to be comparative with that of humans20,32–35. In the clinical
setting however, results are often not as readily transferable possibly because the physical
structure or more specifically the biomechanics and or load dispersion through soft tissues,
joints, and bone differs between humans and animals. We conducted a search using PubMed and
Medline in April 2013 with combinations of the following key words: platelet rich plasma,
platelet-rich plasma, growth factors, orthopaedic pathologies, sports medicine, muscle, tendon,
bone, and ligament. Studies were eligible for review if they explored the effectiveness of PRP in
muscle, tendon, bone, or ligaments in humans. We further reduced this volume of literature by
selecting those studies with the highest levels of evidence36. Each relevant study is presented in
brief summary showing all significant findings for consideration of implications of PRP in
orthopedic pathologies. Study details are summarized in Tables 1 and 2.
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Study

Study
Design

Control
Groups

Blinded

Sample size

Outcome Measures

Everts et al
(2008)

RCT

Yes

40 (20/20)

VAS, ASES, SIS, ROM

Randelli et al.
(2008)

RCT

Yes

53 (26/27)

Devos et al.
(2010)

RCT

Yes

Creaney et al.
(2011)

RCT

Yes

Castricini et
al. (2011)
Gosens et al.
(2011)

RCT

Yes

RCT

Yes

Cervellin et
al. (2012)
Rha et al.
(2012)
Weber et al.
(2012)
Krogh et al.
(2013)
Klaasen et al.
(2011)

RCT

Yes

Yes
(Patients,
Assessor)
Yes
(Patients,
Assessor)
Yes
(Patients,
Assessor)
Yes
(Patients,
Assessor)
Yes
(Patients)
Yes
(Patients,
Assessor)
Yes (Patient)

RCT

Yes

RCT

Yes

RCT

Yes

Retrospective
Cohort

Yes

Yes (Patient,
Assessor)
Yes (Patient,
Assessor)
Yes (Patient,
Assessor)
No

Validated
Outcome
measures
Yes

Length of
Follow-up
(months)
3

Constant score, VAS, SER,
UCLA, SST, MRI,
Ultrasound
VISA-A, return to sports,
patient satisfaction,

Yes

24

Yes

6

150 (80/70)

PRTEE

Yes

6

80 (43/45)

Constant score, MRI

Yes

(+/-) 20.2

100 (51/49)

VAS, DASH

Yes

24

40 (20/20)

VAS, VISA, MRI

Yes

12

39 (20/19)

SPADI

Yes

6

60 (30/30)

ROM, UCLA, SST, ASES,
MRI
PRTEE, Ultrasound

Yes

12

Yes

12

Radiographs (Brooker
Grading)

Yes

12

54 (27/27)

60 (20/20/20)
161 (76/91)
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Prospective
cohort
Pilot study

Yes

Retrospective
Cohort

Orrego et al.
(2008)
Nin et al.
(2009)
Patel et al.
(2013)

Wei et al.
(2012)
WrightCarpenter et
al. (2004)
Wetzel et al.
(2013)

Yes (Patient,
Assessor)
No

254
(85/101/90)
29 (18/11)

AOFAS, Radiographs, CT
Scan
Return to sport, MRI

Yes

72

No

(+/-) 17.7

Yes

No (Not
mentioned)

15 (10/5)

No

RCT

Yes

Yes

Yes

108
(26/27/28/27)
100 (50/50)

4.5
(treatment),
2 (control)
6

RCT

Yes (Patient,
Assessor)
Yes (Patient,
Assessor)

VAS, Return to work, Return
to sport, Patient-reported
satisfaction, NPRS
MRI, Lysholm Score, IKDC

Yes

24

RCT

Yes

Yes (Patient,
Assessor)

78 (27/25/26)

Yes

6

Yes

VAS, Anterior laxity, IKDC,
Inflammatory parameters,
Radiographs, MRI
WOMAC, VAS, Patient
satisfaction

Table 1 Summary of Studies
Abbreviations: RCT, randomized controlled trial; ASES, American Should and Elbow Surgeons; SIS, Shoulder Index Score; VAS,
visual analog scale; SER, strength in external rotation; SST, simple shoulder test; UCLA, University of California; VISA-A, Victorian
Institute of Sports Assessment – Achilles; DASH, Disabilities of the Arm, Shoulder, and Hand; PRTEE, Patient-Related Tennis Elbow
Evaluation; NPRS, Nirschl Phase Rating Scale; IKDC, International Knee Documentation Committee score; WOMAC, Western
Ontario and McMaster Universities Arthritis Index questionnaire; AOFAS, American Orthopaedic Foot and Ankle Society; SPADI,
Shoulder Pain And Disability Index; MRI, Magnetic Resonance Imaging
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Study

Study Design

No. Of

Included study designs

Studies
Sheth et al. (2012)

Systematic Review

33

and Meta-analysis
Chahal et al.

Systematic Review

(2012)

and Meta-analysis

RCT (n = 23), Prospective cohort (n =
10)

5

Table 2 Systematic Reviews and Meta-analyses

RCT (n = 2), Prospective cohort (n = 3)
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PRP in Tendon Healing
Everts et al37 published results of a randomized controlled trial (RCT) that evaluated the use of
platelet-leukocyte gel (PLG) in open subacromial decompression surgery for 40 patients
(treatment=20, control=20) with chronic impingement syndrome of the shoulder. At 6 weeks the
PLG group showed significant improvement in visual analog scale (VAS) pain scores that were
part of the American Shoulder and Elbow Surgeons tool (P<0.05). Patients with PLG also used
significantly less pain medication (P<0.05) and scored significantly better on the shoulder index
score postoperatively (P<0.05). Patients with PLG had significantly improved scores on the
activities of daily living questionnaire 2 weeks postoperatively (P<0.05) and demonstrated
greater range of motion (ROM) improvement at 2 weeks (P<0.05).
Randelli et al38 published results of a RCT for the effectiveness of PRP in tendon healing in
patients undergoing arthroscopic repair of a complete rotator cuff tear. Patients received either an
intraoperative application of PRP with an autologous thrombin component (n=26) or no
treatment in the control group (n=27), and were followed up for over 2 years. Outcome measures
were VAS for pain, Constant score, strength in external rotation (SER), Simple Shoulder Test
(SST), University of California-Los Angeles (UCLA), and tendon integrity assessed using
magnetic resonance imaging (MRI). The pain score in the treatment group was lower than the
control group at 3, 7, 14, and 30 days after surgery (P<0.05). Scores on the SST, UCLA,
Constant scores, and SER were significantly better in the treatment group than the control group
at 3 months after surgery (P<0.05). There was no difference between the groups at 6, 12, and 24
months. The follow-up MRI showed no significant difference in the healing rate of the rotator
cuff tear. In the subgroup of grade 1 and 2 tears, with less retraction, SER in the PRP group was
significantly higher at 3, 6, 12, and 24 months postoperative (P<0.05).
De Vos et al39 performed a RCT of 54 patients with chronic Achilles tendinopathy. Patients were
randomized to receive a PRP injection (n=27) or placebo (n=27). The validated Victorian
Institute of Sports Assessment-Achilles (VISA-A) questionnaire, which evaluated pain score and
activity level, was completed at baseline and 6, 12, and 24 weeks. Secondary outcomes included
subjective patient satisfaction, return to sports, and adherence to eccentric exercises. Authors

13

found no statistically significant differences between treatment groups for any of their outcomes
(P>0.05).
Creaney et al40 conducted a RCT comparing autologous blood injection (n=70) and PRP (n=80)
in patients with elbow tendinopathy who had failed conservative physical therapy. Each patient
received 2 injections: 1 at baseline and 1 a month later. Patient-related tennis elbow evaluation
was the primary outcome measure which patients completed at baseline, 1, 3, and 6 months.
Authors found no statistically significant differences in the improvement of scores between
groups (P<0.05).
Castricini et al41 completed a RCT that included 88 patients with a rotator cuff tear who received
arthroscopic rotator cuff repair with (n=43) or without (n=45) augmentation with autologous
platelet-rich fibrin matrix. The primary outcome was the postoperative difference in the Constant
score between the 2 groups, and the secondary outcome was the integrity of the repaired rotator
cuff, as evaluated by MRI. The authors found no statistically significant differences between
groups for either of the outcome measures (P<0.05).
Gosens et al42 published the 2-year results for an ongoing study comparing PRP and
corticosteroid injection for the treatment of chronic lateral epicondylitis. One hundred patients
were randomized to a leukocyte-enriched PRP group (n=51) or the corticosteroid group (n=49).
The primary outcomes were the pain VAS scores and the DASH outcome scores. The PRP group
had a statistically significant reduction of 25% on pain and DASH scores (P<0.05) without a
reintervention after 2 years. When baseline pain and DASH scores were compared with the
scores at 2-year follow-up, both groups significantly improved across time (intention-to-treat
principle). However, the DASH scores of the corticosteroid group returned to baseline levels,
whereas those of the PRP group significantly improved (as-treated principle; P<0.05).
In a RCT, Cervellin et al43 evaluated the effectiveness of PRP in 40 young athletes following
bone-patellar tendon-bone technique for anterior cruciate ligament (ACL) pathologies. Patients
were randomized to undergo ACL reconstruction with patellar tendon grafts and bone-patellar
tendon-bone technique with (n=20) or without (n=20) PRP gel applied to the donor site.
Outcome measures included reduction in anterior knee pain, kneeling pain, and donor-site
morbidity as evidenced by evaluation of VISA and VAS scoring scales and MRI analysis of the
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tendon and bone defect. At 12-month follow-up, VISA scores were significantly higher in the
patients treated with PRP (P<0.05). No other outcomes were found to be statistically different.
Rha et al44 compared the effects of 2 PRP injections (n=20) with those of 2 dry needling
injections (n=19) in patients with a supraspinatus tendon lesion (tendinosis or a partial tear
<1cm). The outcomes included the Shoulder Pain and Disability Index, passive ROM, a
physician global rating scale at the 6-month follow-up, and an ultrasound measurement. There
was a statistically significant improvement in clinical outcomes in the PRP group (P<0.05) from
6 weeks to 6 months. At 6 months the mean Shoulder Pain and Disability Index also showed a
statistically significant difference between groups in favor of the PRP treatment (P<0.05).
Weber et al45 conducted a RCT to compare the effectiveness of platelet-rich fibrin matrix (n=30)
to a control group with no injection (n=30), in the treatment of arthroscopic rotator cuff repair.
Outcome measures collected over 1 year included pain VAS, ROM, UCLA, and SST scores, and
recorded narcotic consumption. Mean UCLA shoulder scores were significantly better for the
PRP group at 1 year (P<0.05). There were no statistically significant differences found for the
other outcomes.
Krogh et al46 compared a single injection of PRP (n=20) to a glucocorticoid injection (n=20) and
a placebo (saline; n=20) in a RCT for patients with chronic lateral elbow epicondylitis. The
primary outcome was reduction in pain after 3 months using the PRETEE questionnaire, and
secondary outcomes were ultrasonographic changes in tendon thickness and color Doppler
activity. Glucocorticoid reduced pain more effectively than did both saline and PRP at 1 month
(P<0.05). Glucocorticoid also showed statistically significant reduction of color Doppler activity
and reduced tendon thickness (P<0.05) compared with both PRP and saline.

PRP in Bone Healing
Klaassen and Pietrzak47 completed a retrospective, controlled clinical study that examined the
effect of PRP application during closure after total hip arthroplasty on heterotopic ossification.
The PRP group consisted of 76 patients with 85 hips evaluated and the control group consisted of
91 patients with 94 hips evaluated. The primary outcome was the unwanted presence of
heterotopic ossification evaluated using radiographs and the Brooker classification immediate
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postoperative, 6 weeks, 3 months, and 1 year. No significant differences were found between
groups.
Wei et al48 conducted a prospective cohort study to compare the effectiveness of PRP in the
treatment of displaced intra-articular calcaneal fractures. Patients received one of 3 treatments:
autograft alone (n=101), allograft combined with PRP (n=85), or allograft alone (n=90).
Outcome measures included radiographic imaging and 3-dimensional computed tomography to
assess the thalamic portion, Bohler angle, the crucial angle of Gissane, and the height, width and
length of the calcaneum. The American Orthopedic Foot and Ankle Society ankle-hind-foot
scoring system was used to evaluate the hindfoot function at intervals over a period of 6 years.
There were statistically significant improvements for patients in the autograft and allograft with
PRP treatment groups at 2 and 6 years compared with the allograft alone group (P<0.05) in
radiographic assessments.

PRP in Muscle Healing
Wright-Carpenter et al49 conducted a pilot study on the effects of autologous conditioned serum
(n=18) compared with a control group using a combination of deproteinized dialysate from
bovine blood and a homeopathic anti-inflammatory drug (Actovigan/Traumeel; n=11). Patients
were professional sportsmen with a variety of lower limb muscle strains. Primary outcomes
included time to return to sport and MRI. The autologous conditioned serum group returned to
full sport participation statistically sooner than the control group (P<0.05).
Wetzel et al50 compared the effectiveness of PRP in proximal hamstring pathologies in a
retrospective cohort of patients. The authors included patients in an analysis who had failed
traditional conservative treatment and had received a PRP injection (n=15) and compared them
to a cohort who received no treatment (n=5). Outcomes included pretreatment and posttreatment
VAS pain scores, Nirschl Phase Rating Scale scores, and return to sport. Both groups showed
significant improvements from baseline scores, but there were no significant differences found
between groups (P>0.05).
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Intra-articular Application of PRP
Orrego et al51 completed a RCT to determine whether the use of platelet concentrate (PC) and
bone plug (BP) accelerates healing in ACL reconstruction. Patients were randomized to PC
(n=26), BP (n=28), combination of PC and BP (n=27), and a control group (n=27). Maturation of
the graft was evaluated at the femoral tunnel using MRI maturation criteria defined by a lowintensity signal, absence of osteoligamentous interface, and no widening of the femoral tunnel.
Subjective and objective evaluations using the Lysholm and International Knee Documentation
Committee scores were performed preoperatively and 6 months after surgery. The only
significant difference was found at 6 months in the presence of low-intensity mature graft signal
at the femoral tunnel in 78% of the BP group and in 100% of the PC group (P<0.05). Tunnel
widening (negative result) was seen in 11% of the patients in the BP group versus 41% of the
patients in the control group (P<0.05).
Nin et al52 evaluated the use of platelet-derived growth factor in primary ACL reconstruction
with bone-patellar tendon-bone allograft in a RCT of 100 patients. Patients received either
platelet-enriched gel (n=50) or a nongel (n=50). Patients were followed at intervals for a period
of 24 months and outcome measures were the pain VAS, anterior laxity assessed using an
arthrometer, the International Knee Documentation Committee scores, C-reactive protein levels,
knee circumference, MRI and radiographic measures. The results did not show any statistically
significant differences between the groups for inflammatory parameters, MRI appearance of the
graft, and clinical evaluation scores (P>0.05).
Patel et al53 assessed the use of PRP in a RCT of 78 patients (156 knees) with bilateral
osteoarthritis of the knee. Patients were divided into 3 treatment groups: group A (52 knees)
received a single injection of PRP, group B (50 knees) received 2 injections of PRP 3 weeks
apart, and group C (46 knees) received a single injection of normal saline. Outcome measures
included the Western Ontario and McMaster (WOMAC) Universities Arthritis Index
questionnaire and pain VAS. Patients were assessed at baseline, 6 weeks, 3 months, and 6
months after treatment. Groups A and B showed significant improvements in all WOMAC
parameters and pain VASs at all time points when compared with group C (P<0.05), but no
difference observed when comparing groups A and B (P>0.05).
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Systematic Reviews
In a systematic review and meta-analysis conducted by Sheth et al54 that included most studies
already described, pain and improved healing and function was evaluated in patients with
orthopedic pathologies after the use of PRP. Twenty-three randomized trials and 10 prospective
cohort studies met the eligibility criteria. However, the authors concluded that among the
identified studies, the PRP products utilized were too dissimilar from each other to justify
making a broad statement about the effectiveness of all PRP products and that more studies need
to be conducted so that future reviews could present independent analyses by PRP product.
Chahal et al55 completed a systematic review of the literature and subsequent meta-analysis on
the clinical efficacy of PRP in arthroscopic rotator cuff repair of patients with full-thickness
rotator cuff tears. Five studies (2 randomized and 3 nonrandomized with comparative control
groups) met the inclusion criteria, with a total of 261 patients. Quantitative synthesis of all 5
studies using a random effects model showed that there was no statistically significant difference
in the overall rate of rotator cuff retears between patients treated with PRP and those treated
without PRP (risk ratio, 0.77; 95% confidence interval, 0.48-1.23). There were also no
statistically significant differences in the pooled Constant score, SST, American Shoulder and
Elbow Surgeons, UCLA, or SANE score.

Conclusion
There are currently no clear indications for the use of PRP in orthopedic pathologies. There is a
lack of homogenous, high level studies evaluating the effect of PRP in orthopedic pathologies,
thus precluding attempts to pool results across studies and preventing us from making
conclusions with any degree of certainty.
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Chapter 3 Ultrasound versus palpation guided PRP injections in
tendon and muscle pathologies: A systematic review and metaanalysis of randomized and non-randomized trials
Abstract
Background: There is controversy as to whether the effectiveness of platelet rich plasma (PRP)
injections for non-operative treatment of muscle and tendon pathologies is affected by the
method of administration. Compared to palpation alone, ultrasound guided injections may offer
improved accuracy and subsequent greater effectiveness of PRP for tendon and muscle
pathologies.
Objectives: The purpose of this systematic review and meta-analysis was to evaluate the
effectiveness of ultrasound guided versus palpation guided PRP injections for the treatment of
tendon and muscle pathologies.
Search methods: We searched Pubmed, Medline Ovid, CINAHL, Scopus, SportDiscus,
EMBASE, and Cochrane Library from inception to December 2014. We also searched references
of recently published review papers and systematic reviews.
Selection criteria: We included Level I, II, and III comparative studies evaluating PRP injection
versus a non-PRP control for the non-operative treatment of muscle and/or tendon injury.
Data collection and analysis: Two independent reviewers assessed the titles and abstracts of
5178 studies. Seventy-one studies were identified for full text review, and 26 studies were
included in the final analysis. We used a modified version of the Cochrane Collaboration tool to
assess risk of bias of included studies. We included 18 studies in our meta-analysis. There were
no studies directly comparing ultrasound versus palpation guided injections of PRP, thus we used
an indirect comparison using random-effects with associated P values and 95% confidence
intervals (CI). We assessed heterogeneity of studies using an I2 and Tau2 statistic and Chi2 test.
Specifically, we expected larger effects in studies sponsored by an interested party versus not,
and in those studies with a high risk of bias versus not. We also thought heterogeneity may be
explained by creating subgroups and therefore explored whether heterogeneity was decreased if
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we separated studies that evaluated outcomes in tendon versus muscle, acute (<3 months
symptom duration) versus chronic (>3 months symptom duration) pathologies, active control
versus sham or placebo, platelet concentration (≤3 versus >3 times baseline blood),and intraarticular injection versus not.
Main results: We found no statistically significant difference in failure rates between patients
whose PRP injection was ultrasound-guided or not. There was also no significant difference in
pain at less than two months, two to three months, and six months following PRP injection.
Disability and functional outcomes at six months had high heterogeneity which could not be
explained by our a priori expectations. Therefore, we were unable to make any definitive
conclusions about the difference in disability and functional outcomes between ultrasound versus
palpation guided injections.
Conclusion: There is no evidence to date that ultrasound-guided injection of PRP offers better
outcomes than palpation alone.
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Introduction
Over the past decade, the body of literature evaluating the effectiveness of platelet rich plasma
(PRP) for the treatment of musculoskeletal pathologies has increased. Its purported regenerative
properties drive its continued use as a treatment for tendon, muscle, bone and cartilage, while the
autologous nature of PRP and relative ease of preparation, and contribute to its appeal.
Platelets are discoid cells that contain over 30 bioactive proteins in the form of growth factors1.
At the time of injury, platelets are activated in the presence of damaged tissue and aggregate
together to release the growth factors which stimulate the inflammatory response and initial
healing process2. PRP is a concentrated solution of blood platelets suspended in plasma. By
injecting PRP in the injured area, the localized concentration of these growth factors may
accelerate tissue and wound healing3,4.
PRP is obtained from the venous blood of the patient. The process of centrifugation separates the
blood into a distinctly layered solution of red blood cells and concentrated platelets in plasma.
The PRP is then extracted and injected into the area of injury. Variability in the process depends
on the system used and may include variations in time and speed of centrifugation, as well as the
addition of an anticoagulant prior to centrifugation and/or an activator shortly before the
injection5.
A number of studies have investigated the effectiveness of PRP injections for the non-operative
treatment of tendon pathologies6–9, and a limited few in muscle pathologies10–12. The results,
however, remain inconclusive with a continued need for higher powered randomized controlled
trials with standardized procedures including preparation methods, administration techniques,
and evaluation of outcomes13,14,15.
One area of considerable debate is whether patient outcomes are more favourable when
clinicians use ultrasound to guide the placement of the injection versus relying on palpation
alone. Critics argue that neglecting to use ultrasound to guide PRP injections may decrease the
accuracy of the placement of the solution, in turn decreasing the effectiveness of PRP16,17.
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Hall et al.18 defined accuracy of an injection treatment as the placement of the needle tip in the
target area of the joint or tissue. The accuracy of an injection may be highly dependent on the
target structure (i.e. joint, tendon, or muscle) and expertise of the clinician. Specifically, injured
tendon and muscle structures are easier to locate via palpation compared to intra-articular
structures. The gap in an Achilles tendon rupture, for example, is easier to locate via palpation
than an intra-articular injection for rotator cuff tendinosis. For this reason, most published studies
evaluating the effectiveness of ultrasound guided versus palpation guided injections have
focused on intra-articular pathologies, and less on tendon, with even fewer focusing on muscle.
For example, in 80 cadavers, Patel et al (2012)19 compared the effectiveness of ultrasound guided
versus palpation guided injections in the glenohumeral joint and found significantly greater
accuracy for the ultrasound guided approach (92.5%) over the palpation guided injections
(72.5%). Similarly, Peck et al (2010)20 compared the accuracy of ultrasound (n=10) versus
palpation (n=10) guided injections in the acromioclavicular joint of unembalmed cadavers and
found significantly greater accuracy in the ultrasound (100%) compared to the palpation guided
application (40%) (p < 0.05).
Conversely, in living humans with complaints about an intra-articular structure, Rutten et al.21
reported 100% accuracy for both ultrasound (n = 10) and palpation guided (n = 10) injections of
the subacromial-subdeltoid bursa in a RCT of patients with shoulder impingement syndrome (p >
0.05). In a study evaluating shoulder pain following intra-articular injection for soft tissue and
joint pathologies of the shoulder, Uncuncu et al.22 found a significant improvement (p < 0.05) in
the VAS pain scores and Constant scores in patients who received ultrasound guided injections
(n = 30) versus anatomical landmark-guided injections (n = 30) of corticosteroids. Similarly, in a
RCT by Zufferey et al.23, the authors found a statistically significant improvement (p < 0.05) in
pain at rest and percentage of good responders (defined as greater than 50% reduction in pain) at
two and six weeks follow up in patients who received ultrasound guided (n = 27) versus those
who received palpation guided (n = 29) injections of corticosteroids for the treatment of shoulder
pain. Naredo et al.24 also found a statistically significant improvement (p < 0.05) of VAS pain
scores and shoulder function assessment (SFA) scores at six weeks, in patients randomized to
receive ultrasound guided injections (n = 21) versus palpation guided injections (n = 20) of
corticosteroids for painful shoulder pathology.
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Conversely, Hashiuchi et al.25 published the results of a randomized controlled trial comparing
the accuracy of ultrasound (n=15) versus palpation guided injections (n=15) of the biceps tendon
sheath (tendon versus intra-articular pathology), a palpable tendon. A blinded assessor judged the
presence of a contrast agent within the tendon sheath using a CT scan and found that the
ultrasound guided injections had significantly greater accuracy (86.7% versus 26.7%) in the
injection reaching the target area within the tendon sheath (p < 0.05). Regarding patient
outcomes, in 2011, Zhang et al.26 found a statistically significant improvement of VAS pain
scores and Constant-Murley scores (p < 0.05) for ultrasound guided injections in patients with
biceps brachii tendinitis at an average follow up of 31 weeks in a RCT comparing ultrasound (n
= 53) versus palpation (n = 45) guided corticosteroid injections.
Li et al. 27 published a systematic review in 2014 comparing the effectiveness of ultrasound
versus palpation guided corticosteroid injections in 149 patients with plantar fasciitis. The
authors found a statistically significant greater improvement in the ultrasound-guided group for
tenderness threshold, plantar fascia thickness, and hypoechogenicity (p < 0.05). However, there
was no significant difference between treatments for VAS pain, Heel Tenderness Index (HTI),
and response rate defined as complete relief of symptoms after one injection (p > 0.05). In
summary, ultrasound guided injections may be more accurate especially for intra-articular
injections, but whether or not this translates to better outcomes seems more likely for intraarticular pathology than tendon or muscle pathology.
To date, there are no published studies directly comparing ultrasound versus palpation guided
injections for PRP in musculoskeletal pathologies. Therefore, we conducted a systematic review
and meta-analysis to evaluate the effectiveness of ultrasound versus palpation guided injections
of PRP to reduce pain and improve function for patients with tendon and muscle pathologies.

Methods
Protocol
We followed the PRISMA guidelines for reporting a systematic review and meta-analysis28.
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Eligibility Criteria
We included studies that compared the effectiveness of PRP injections versus a non-PRP control
group. Inclusion criteria consisted of human studies evaluating treatment of muscle and/or
tendon pathologies using a non-surgical approach, with an evidence level of I, II, or III
comparative design. We excluded animal, cadaveric, and lab studies; and studies evaluating
bone, ligament, cartilage, and wound care pathologies.

Information sources and searches
We consulted with a university librarian to aid with our search of Pubmed, Medline Ovid,
CINAHL, Scopus, SportDiscus, EMBASE, and Cochrane Library from inception to December
2014 (Appendix 3). We also searched the references of recently published reviews and
systematic reviews evaluating the effectiveness of PRP in musculoskeletal pathologies29–34. Our
keyword search included “muscle or tendon” combined with variations of the terms “platelet rich
plasma” and “injection”.

Study Selection
Two reviewers (N.K. and L.C.) independently read the titles and abstracts to determine study
eligibility. We reviewed the full text of any study classified by either reviewer as eligible or
uncertain. The same independent reviewers screened the full text articles using the same
eligibility criteria. Any disagreement was resolved by an independent third party (A.R.). We
completed an inter-rater agreement assessment for categorical data for the full text review using
a Kappa statistic.

Data collection process
Two reviewers (N.K. and A.R.) independently extracted data from eligible studies.
Disagreements between reviewers were resolved by discussion and remaining disagreements
were adjudicated by an arbitrator (D.B.).
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Data items
We extracted patient population information, treatment and control used, and outcome measures.
Additionally, we included details of the diagnosis, symptom duration, and the addition of
anticoagulants and/or activators to the injection procedure. We contacted the authors of seven
studies to obtain additional information or data. We received additional data from five authors35–
38

, and no response from two authors of three studies39–41.

Risk of bias in individual studies
Two independent reviewers (N.K. and L.C.) assessed the risk of bias for each study using a
modified version of the Cochrane Collaboration’s tool for assessing risk of bias in randomized
trials42. Disagreements between reviewers were resolved by discussion and remaining issues
were adjudicated by one of two arbitrators (A.R. and D.B.).We rated the domains for each study
as “high risk” of bias, “low risk” of bias, or “unclear risk”. A study was classified as “high risk”
if the particular criteria that posed a threat to the internal validity was not adequately prevented.
A “low risk” of bias meant that the study took all possible precautions to protect the internal
validity. We labelled the study as having an “unclear risk” of bias when there was limited
information from which to assess bias. Risk of bias guidelines are described in Table 3.
Risk of bias guidelines
RCT's
Domain

Description

Sequence
generation

Judged on the likelihood of the method to generate a randomization
sequence (e.g. random computer generated (“low”) versus odd or even date
of birth (“high”)) that will result in balanced treatment groups
Judged on the effectiveness of the study protocol to reduce the
predictability of group allocation (e.g. open list (“high”) versus
sequentially numbered, opaque, sealed envelopes (“moderate”) versus list
of managed independently or by computer with checks for duplicate or
withdrawn patients (“low”).
Judged on the ability of the protocol to blind the patient, caregiver, and/or
outcomes assessor where possible, so as not to influence the outcomes

Allocation
concealment

Blinding
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Attrition

Reporting

Other

Judged on how likely missing data was related to the treatment or outcome;
the balance of missing data between treatment groups; and how likely
missing data would influence the results (tolerance).
Judged on the study results being reported as specified in the study
protocol (i.e. all primary and secondary outcomes were reported using the
pre-specified measurements and analyses of all data in its entirety).
Judged on the presence of the occurrence of another factor that may have
influenced the study results (e.g. study stopped early or fraudulent claims).
Cohort studies

Domain

Description

Selection bias

Judged on the population sampling method and the unbiased allocation of
participants to the treatment groups.
Determined by the balance of participant baseline characteristics between
treatment groups.

Balance of
prognostic
factors
Unbiased
outcome
assessment
Attrition

Reporting

Other

Judged on the ability of the protocol to blind the patient, caregiver, and/or
outcomes assessor where possible, so as not to influence the outcomes
Judged on how likely missing data was related to the treatment or outcome;
the balance of missing data between treatment groups; and how likely
missing data would influence the results (tolerance).
Judged on the study results being reported as specified in the study
protocol (i.e. all primary and secondary outcomes were reported using the
pre-specified measurements and analyses of all data in its entirety).
Judged on the presence of the occurrence of another factor that may have
influenced the study results (e.g. study stopped early or fraudulent claims).

Table 3 Risk of bias assessment tool used for RCT’s and Cohort studies

Summary measures
We analysed pooled data using standard meta-analysis methods with Review Manager (version
5.3)43. We consulted with an orthopaedic surgeon (K.W.) to establish common follow up times
and outcome measures amongst the studies. We calculated differences between treatment groups
using odds ratios with 95% CI for dichotomous data. For continuous data we used standardized
mean differences (SMD) with 95% CI for comparisons measuring the same outcome using
different scales44 (Cochrane handbook).
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Synthesis of results
We extracted data from studies to compare failure rates as defined by the individual study. If
more than one time point was provided in studies, we used the final follow up scores in the
analysis. For the continuous outcome measure (pain and patient-reported disability and function)
we conducted two analyses at each follow up time point; a change score (final outcome –
baseline) and a raw score (final outcome only). For analyses evaluating a pain VAS some
studies reported a score from a 10 cm line ranging from 0-10 while others reported a score from
0-100. We converted scores on a scale of 0-100 to a standardized scale of 0-10 prior to pooling
the results. We extracted scores of VAS pain scales at three different time intervals: 1) less than
two months, 2) two to three months, and 3) six months post-injection.
We compared change in disability and functional outcome scores for ultrasound versus palpation
studies at six months follow up. We standardized scores to a scale where a lower score represents
worse ability or function.
If not already provided, we converted scores for each study to a mean and standard deviation of
the change in score from baseline. When a mean and range were provided, we calculated an
estimated standard deviation as follows:
(upper limit – lower limit)/4
When a mean and confidence intervals were provided, we calculated the standard deviation as
follows (Cochrane handbook 7.7.3.2).
SD = √𝑛 x (Upper limit – Lower limit)/3.92
We found no studies that directly compared ultrasound guided PRP injections versus palpation
guided PRP injections. For this reason we completed an indirect comparison of treatment effects
as suggested by Bucher et al.45. For each follow up period of each outcome measure, we
completed subgroup analyses comparing (1) ultrasound guided PRP injections versus control
groups; and (2) palpation guided PRP injections versus control groups. We completed a
comparison of subgroups in RevMan 5.3 which calculated the between subgroup differences
with an associated Chi2, degrees of freedom, p value, and measure of heterogeneity (I2). This test
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takes into consideration the overlap of confidence intervals of the summary estimates in the two
subgroups. If the confidence intervals overlap, there is no difference between the treatments. If
the confidence intervals do not crossover, there is a significant difference in effect of treatment.
We did not perform analyses if there were less than two studies in a subgroup comparison. We
used inverse variance and a random-effects approach for our meta-analyses. We assessed
heterogeneity using a Chi2 test and I2 and Tau2 statistic46, where an I2 greater than or equal to
60% was considered the maximum threshold for total heterogeneity44. For any comparison with
heterogeneity greater than the threshold, we performed additional heterogeneity analyses guided
by our a priori hypotheses. Specifically, we expected larger effects in studies sponsored by an
interested party versus not, and in those studies with a high risk of bias versus not. We also
hypothesized that heterogeneity may be explained by creating subgroups and therefore explored
whether heterogeneity was decreased if we separated studies that evaluated outcomes in tendon
versus muscle, acute (<3 months symptom duration) versus chronic (>3 months symptom
duration) pathologies, active control versus sham or placebo, platelet concentration (≤3 versus >3
times baseline blood), and intrarticular versus palpable structures.

Results
Study selection
Our search yielded 8601 studies (Fig. 1). We identified ten additional studies from the reference
lists of review papers. After removal of duplicates, 5179 titles and abstracts remained; 5108
studies were excluded and 71 studies underwent full text review. Following full text review, 26
studies were determined eligible. Inter-rater agreement was excellent (κ=0.88).

Study characteristics
Table 4 and Table 5 describe the included studies. Fourteen studies used ultrasound guided
injections during PRP administration, and 12 used palpation alone. Eighteen of the included
studies were randomized controlled trials, four were prospective comparative studies and four
were retrospective comparative studies.
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# of records identified through
database searching (n = 8601)

# of additional records identified
through other sources (n = 10)

# of records removed for
duplication
(n = 3432)
# of records screened for titles
and abstracts (n = 5179)

# of records screened for full
text review
(n = 71)

# of articles included in
qualitative synthesis (n =
26) (excluding 3 duplicate
publications)

# of articles included in
quantitative synthesis (metaanalysis)
(n = 18)
Figure 1 Flow diagram of search process of studies

# of records excluded
through titles and abstract
screening
(n = 5108)
# of full text articles
excluded, with reasons
n=18 Conference abstracts
n=10 Review, Editorial,
Commentary papers
n=5 Case series
n=3 Protocol papers
n=2 Animal studies
n=2 Surgical interventions
n=1 Compares PRP to PRP
n=1 Exam paper
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Study

Design

Pathology

¶PRP treatment
(Preparation
System and
other)
RecoverTM Kit,
Biomet

Control

N size

Outcomes

Follow
ups

Additives

Results

RCT

Achilles
tendionpathy

Saline

27/27

6 wks; 3,
6 mos; 1
yr

Citrate

No
differen
ce

Elbow
tendinopathy

Unspecified

Autologous
blood

80/70

VISA-A, Patient
satisfaction, Return
to Sports,
Adherence to
eccentric exercise,
Ultrasound
measures
PRTEE

RCT

1, 3, 6
mos

RCT

Chronic
Lateral
Epicondylitis

RecoverTM Kit,
Biomet

Autologous
blood

14/14

VAS pain,
Liverpool elbow
score

6 wks; 3,
6 mos

Favour
ed
control
No
differen
ce

RCT

Rotator cuff
(tendinosis or
partial tear)
Muscle injury

Prosys PRP Kit

Dry needling

20/19

3, 6 mos

Unspecified and
Conservative
therapy

Conservative
therapy

15/15

1, 7, 14,
21 days;
1 mos

Trisodium
citrate
buffer

No
differen
ce

ACP® Double
Syringe, Arthrex
and
Conservative

1)
Extracorpore
al shock
wave therapy
and
Conservative;
2)

19/19/16

SPADI, ROM,
Adverse effects,
Ultrasound
VAS pain,
Strength, ROM,
Resistance
assessment, Global
function score
VAS pain, AOFAS
ankle-hindfoot
scale

Citrate
anticoagul
ation
Anticoagu
lant
(unspecifi
ed)
ACD-A

1, 3, 6
mos

None

No
differen
ce

de Vos
201047/ de
Jonge
201138/ de
Vos
201115
Creaney
201136
Thanasas
201148

Rha
201249
RCT
Bubnov
201337

RCT
Chew
201350

Plantar
fasciitis

Favour
ed PRP

36

RCT

Chronic rotator
cuff
tendinopathy

Recover Kit,
Biomet (GPS III
System)

RCT

Lateral
Epicondylitis

Recover Kit,
Biomet (GPS III
System)

1) Saline;2)
Glucocorticoi
d

20/20/20

Retrospe
ctive
comparat
ive study
RCT

Hamstring
pathologies

Recover Kit,
Biomet (GPS III
System) and
Physiotherapy
Unspecified

Physiotherap
y

5/5

WORC, SPADI,
VAS pain with
Neer Impingement
Sign, ROM
PRTEE, Ultrsound
measures, pain
score.adverse
events
Return to sport

30/30

VAS pain

1, 3, 6
mos

RCT

Jumper's knee

Methyl
prednisolone
acetate
(steroid)
Extracorpore
al shock
wave therapy

23/23

VISA-P, VAS
pain, modified
Blazina

RCT

Patellar
tendinopathy

Dry needling

10/13

RCT

Grade 2
Hamstring
muscle
pathologies
Hamstring
pathologies

Physiotherap
y

14/14

Saline

41/39

Kesikbur
un 201335

Krogh
201340

Rettig
201351

Tiwari
201352

Plantar
fasciitis

Vetrano
20136

Dragoo
201453
Hamid
201411
RCT
Reurink
201454

Conservative
alone
Saline

MyCells®
Autologous
Platelet
Preparation
System
Recover Kit,
Biomet (GPS III
System)
Recover Kit,
Biomet (GPS III
System)and
Physiotherapy
ACP® Double
Syringe, Arthrex

20/20

3, 6 wks;
3, 6 mos;
1 yr

None

No
differen
ce

1, 3, 6
mos; 1 yr

Sodium
citrate

No
differen
ce

6 mos

ACD-A,
sodium
bicarbonat
e
None

No
differen
ce

2, 6, 12
mos

ACD-A

Favour
ed PRP

VISA, Tegner,
Lysholm, VAS
pain, SF-12
Return to sport,
BPI-SF pain scores

3, 6 wks;
2, 3, 6
mos
2.5 mos

None

No
differen
ce
Favour
ed PRP

Return to sport,
Rate of reinjury

2, 6 mos

None

None

No
differen
ce

No
differen
ce
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Table 4 Ultrasound guided study details
RCT = randomized controlled trial, PRTEE = patient-rated tennis elbow evaluation, VISA-A = Victorian institute of sport assessment
scale Achilles, VAS = visual analogue scale, SF-12 = short form 12, SPADI = shoulder pain and disability index, ROM = range of
motion, ACD-A = anticoagulant citrate dextrose solution A, BPI-SF = brief pain inventory short form, WORC = Western Ontario
rotator cuff index, wks = weeks, mos = months, yr = year. ¶See Appendix 1 for system details
Study

Design

Pathology

Retrospective
comparative
study

Muscle
pathologies
(variety)

Mishra
200641

Prospective
comparative
study

Chronic
elbow
tendinosis

Filardo
201055

Prospective
comparative
study

Chronic
refractory
patellar
tendinopathy

RCT

Lateral
Epicondylitis

WrightCarpent
er 200412

Peerboo
ms

¶PRP
treatment
(Preparation
System and
other)
Orthokine®,
Autologous
Conditioned
Serum
Recover Kit,
Biomet (GPS
III System)

Control

N size

Outcomes

Follow
up

Additives

Results

Actovegin/
Traumeel

18/11

Return to
sport, MRI
analysis

16 days

None

Favour
ed PRP

Bupivacaine
with
epinepherine

15/5

VAS pain,
Modified
Mayo score

4wks;
2, 6
mos

Favour
ed PRP

Not mentioned
and
Physiotherapy

Physiotherap
y

15/16

1, 6
mos

Recover Kit,
Biomet (GPS
III System)

Corticosteroi
ds

51/49

Tegner, EQ
VAS, pain
scale,
complications,
return to sport,
patient
satisfaction
VAS pain
scale,
Disabalities of

Sodium
citrate +
Sodium
bicarbonat
e buffer
Calcium
cholride

1, 2, 3,
6, 12,
24 mos

Sodium
citrate +
Sodium

No
differen
ce

Favour
ed PRP
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201056/
Gosens
201157

the Arm,
Shoulder and
Hand (DASH)
Metilpredniza 30/30
VAS pain
lone
scale, Roles
and Maudsley
score
Corticosteroi (15/15 VAS, DASH
ds
)/(15/ (elbow), FHSQ
15)
(foot)

Prospective
comparative
study

Plantar
Fasciitis

Not mentioned

RCT

Plantar
Fasciitis &
Tennis Elbow

Not mentioned

RCT

Achilles
tendinopathy

Eccentric
loading
programme

10/10

Retrospective
comparative
study

Hamstring
pathologies

None

10/5

Wetzel
201361

GenisisCS
Component
Concentrating
System
Recover Kit,
Biomet (GPS
III System)

Retrospective
comparative
study

Achilles
tendon

ACP® Double
Syringe,
Arthrex and
Accelerated
Rehabilitation

Accelerated
Rehabilitation

72/73

Kaniki
20147

RCT

Tennis Elbow

Recover Kit,
Biomet (GPS
III System)

Bupivacaine

112/1
13

Aksahin
201258

Omar
201259

Kearney
201360

Mishra
201439

bicarbonat
e buffer
3 wk,
6mos

Calcium

No
differen
ce

6 wks

Citrate
phosphate
dextrose

VISA-A, EQ5D

6wks;
3, 6
mos

Citrate
anticoagul
ant

No
differen
ce (TE)
Favour
ed PRP
(PF)
No
differen
ce

VAS pain,
Nirschl Phase
Rating Scale
Score, Return
to Sport
Strength,
ROM, Calf
circumference,
Leppilahti
scale, AOFAS
(PRP only)
Safety, VAS
with resisted
wrist
extension,
PRTEE,

4.5/2
mos

None

No
differen
ce

6 wks;
3, 6,
12, 18,
24 mos

None

No
differen
ce

1, 2, 3,
6 mos

ACD-A +
sodium
bicarbonat
e

Favour
ed PRP
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RCT

Lateral
Epicondylitis

Rooyagen Kit
Leukocyteenriched PRP

Autologous
Blood

23/22

Prospective
comparative
study

Plantar
fasciitis

Not mentioned

Methylpredni
solone
(steroid)

25/25

Raeissad
at 201462

Say
201463

extended wrist
exam, success
rate
VAS, modified
4, 8
Mayo Clinic
wks
performance
index for the
elbow, and
pressure pain
threshold
(PPT)
VAS, AFAS
6wks, 6
mos

ACD-A

Favour
ed PRP

Sodium
citrate +
calcium
chloride

Favour
ed PRP

Table 5 Palpation alone study details
VAS = visual analogue scale, DASH = disabilities of the arm, shoulder and hand, MRI = magnetic resonance imaging, EQ VAS =
Euroqol visual analogue scale, FHSQ = foot health status questionnaire, PPT = pressure pain threshold, ACD-A = anticoagulant citrate
dextrose solution A, ROM = range of motion, AOFAS AHS = American orthopedic foot and ankle society ankle-hindfoot scale,
AFAS = American foot and ankle score, wks = weeks, mos = months, yr = year. ¶See Appendix 1 for system details
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Risk of Bias within studies
A summary of the risk of bias assessments for RCT’s and cohorts can be found in Table 6 and
Table 7. Most of the RCT’s maintained an overall low risk of bias due to their randomized
design which accounts for sequence generation and allocation concealment when performed
adequately. The majority of cohort studies had an overall risk of bias that was either low or
unclear. The absence of randomization introduces a greater risk of selection bias. However, we
also assessed the demographics table of the included studies to determine if known prognostic
factors were balanced between groups and better understand the likelihood that a selection bias
was present.

Author

Year

Sequence
generation

Allocation
concealment

Blinding

Attrition

Reporting

Other
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Creaney
de Jonge/de Vos
Gosens/Peerbooms
Thanasas
Omar
Rha
Bubnov
Chew
Kearney
Kesikburun
Krogh
Tiwari
Vetrano
Dragoo
Hamid
Mishra
Raeissadat
Reurink

2011
2011
2011
2011
2012
2012
2013
2013
2013
2013
2013
2013
2013
2014
2014
2014
2014
2014

Unclear
Low
Low
Low
Unclear
Low
Unclear
Low
Low
Low
Low
Unclear
Low
Low
Low
Low
Low
Low

Low
Low
Low
Low
Unclear
Low
Unclear
Low
Low
Low
Low
Unclear
Unclear
Low
Low
Low
Unclear
Low

Low
Low
Low
Low
High
Low
High
Low
Low
Low
Low
Unclear
Low
Low
Low
Low
Low
Low

Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
High
Low
Low
Low
Low
High
Low
Low

Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
High
Low
Low
High
Low
High
Low
Low

Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
High
Low
Low
Low
High

Table 6 Risk of bias assessment for RCT’s

Balance of
prognostic
factors

Unbiased
outcome
assessment

Reporting

Other

2004

Unclear

High

Unclear Low

Low

Low

2006
2010
2010
2013
2013
2014
2014

Unclear
Low
High
Low
Unclear
Low
High

High
Low
High
High
Low
Low
Low

Low
Low
Low
Unclear
Low
High
Low

High
Low
Low
High
Low
Low
Low

Low
Low
Low
Low
Low
Low
Low

Table 7 Risk of bias assessment of cohort studies

Attrition

Selection
Bias

WrightCarpenter
Mishra
Aksahin
Filardo
Wetzel
Rettig
Kaniki
Say

Year

Author
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High
Low
Low
Low
Low
High
Low
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Summary results
Failure rates
Failure rates were reported in five studies. Two studies defined failure as less than 25%
improvement of VAS scores from baseline at six months and one year respectively. Two studies
reported patient dissatisfaction as failure at one year, and one study defined less than 25%
improvement of scores from baseline to six months on the PRTEE questionnaire as failure.
We found no statistically significant differences between the treatment effects of ultrasound
versus palpation guided studies for the comparison of failure rates (p = 0.17) (Figure 2).
Heterogeneity of the group differences was moderately low with I2 = 46.5%. The overall
heterogeneity of studies included in the analysis for both treatments was high (I2 = 70%).

Figure 2 Comparison of failure rates in ultrasound (US) versus palpation (non-US) guided
injections of PRP.
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VAS Pain scale outcomes
Pain as measured with the visual analogue scale (VAS) was assessed in 13 of the included
studies. One study measured pain using the BPI-SF pain scores64 which measured pain intensity
as an average of five VAS pain scales with a total score out of 10. Because the metric differed
between studies, we used the standardized mean difference to pool the results.
We found no statistically significant differences between the treatment effects of ultrasound
versus palpation guided injections at less than two months for the change in VAS pain scores
from baseline (p = 0.60) (Fig. 3). Heterogeneity of the group differences was low with I2 = 0%.
In addition, we compared raw scores between treatment groups at less than two months and
found no significant difference in treatment effect between groups (p = 0.37).

Figure 3 Comparison of change in scores from baseline ultrasound (US) versus palpation
(non-US) guided injections of PRP using the VAS pain scale outcome measure at less than
two months follow up.
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Despite statistically favourable outcomes for patients receiving a PRP injection (p <0.01) at two
to three months, there was no evidence to support the use of ultrasound guidance over palpation
alone (p = 0.62). (Fig. 4). Heterogeneity of the group differences was low with I2 = 0%. In
addition, we compared raw scores between treatment groups at two to three months and found no
significant difference in treatment effect between groups (p = 0.22).

Figure 4 Comparison of change in scores from baseline ultrasound (US) versus palpation
(non-US) guided injections of PRP using the VAS pain scale outcome measure at two to
three months follow up.
Despite statistically favourable outcomes for patients receiving a PRP injection (p=0.0001) at six
months, there was no evidence to support the use of ultrasound guidance over palpation alone
(p=0.47). (Fig. 5). Heterogeneity of the group differences was low with I2 = 0%. In addition, we
compared true scores between treatment groups at six months and found no significant difference
in treatment effect between groups (p = 0.64).
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Figure 5 Comparison of change in scores from baseline ultrasound (US) vers of change in
scores from baseline ultrasound (US) versus palpation (non-US) guided injections of PRP
using the VAS pain scale outcome measure at six months follow up.

Disability and functional outcome scores
The outcome measures used in the studies included the DASH, SPADI, VISA-A, VISA-P,
PRTEE, AFAS, and Liverpool Elbow Scale1. Because the metric differed between studies, we
used the standardized mean difference to pool the results. One of the studies included both the
SPADI questionnaire, and the Western Ontario Rotator Cuff index (WORC) as outcome
measures. We chose to use the data of the SPADI in our analysis as it was a region-specific



The DASH is a self-reported, region-specific, 30-item instrument that measures upper-extremity disability and
symptoms on a scale of zero to 100 (0 = no disability). The SPADI is a self-reported, region-specific outcome that
measures current shoulder pain and disability. The VISA-A is a self-reported, region-specific outcome that measures
pain, function in daily living, and sporting activity in Achilles tendon pathology. The VISA-P measures a similar
construct to the VASA-A but is specific to the patella tendon. The PRTEE is a 15-item questionnaire that measures
forearm pain and disability in patients with lateral epicondylitis. The AFAS is a region-specific questionnaire of the
foot and ankle that consists of nine items scored on a scale of 100 (100 = no disability). The Liverpool Elbow Scale
is a region-specific questionnaire that assesses disability, including a question about pain.
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questionnaire like the other included outcomes, as opposed to a disease-specific outcome
measure like the WORC.
There was a statistically significant difference in treatment effect in favour of the palpation
guided studies (p = 0.01) (Fig. 6). However, heterogeneity of the group differences was high
with I2 = 83.5%. We attempted to reduce the heterogeneity by further subgroup analyses of a
priori hypotheses for heterogeneity, but we were unable to adequately reduce I2 to below the
maximum 60% threshold. For example, the heterogeneity decreased to 62.2% with a p = 0.10
when we removed the sham and placebo studies. The removal of either low or high
concentrations of PRP also did not change the heterogeneity. Additional comparison of the raw
scores of disability and functional outcomes at six months produced a non-significant difference
of treatment effect (p = 0.16) with a moderately low I2 of 48.5%.

Figure 6 Comparison of change in scores from baseline for the ultrasound (US) versus
palpation (non-US) guided injections of PRP using disability and functional outcomes at six
months follow up.
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Discussion
Summary of evidence
There are currently no published studies directly comparing the effectiveness of ultrasound
versus palpation guided injections of PRP in musculoskeletal pathologies. In our systematic
review and meta-analysis we compared these two techniques of PRP injection using an indirect
analysis method. There was no significant difference in failure rates between ultrasound and
palpation guided injections or for pain at less than two months, two to three months, or six
months follow up. We found a significant difference between treatment groups in favor of
palpation guided injections for disability and functional outcomes at six months follow up,
however, there was high heterogeneity between treatment groups and therefore superiority of the
palpation guided injection could not be definitively concluded.
We hypothesized that the administration of a PRP injection using ultrasound guidance would
result in better outcomes. However, our results do not support this theory. Thus, there is no
evidence to support the additional cost of equipment and the expertise required to perform
injections under ultrasound guidance.

Limitations
The studies included in our systematic review and meta-analyses reiterated the need for higher
powered and more rigorous randomized controlled trials to determine the effectiveness of PRP.
The high levels of heterogeneity we found in our statistical analyses of disability and functional
outcomes may be reflective of the intrinsic treatment and methodological variations within the
included studies.
There were six different types of PRP preparation systems used, contributing to the heterogeneity
of studies. These systems varied the speed and frequency of the spinning process, and the
method for extraction (some maintain the leukocytes or buffy layer, while others do not)37,53,62
Furthermore, the different preparation systems yielded varying concentrations of PRP, ranging
between two to six times higher than baseline blood. There is currently no standardized
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concentration of platelets deemed essential for the effectiveness of PRP, adding to the
heterogeneity of the treatment effect.
Additionally, the inclusion or omission of an anticoagulant, buffer, and/or an activator during the
PRP preparation varied between studies and preparation systems. This also affected the
concentration of platelets and associated growth factors, and may have introduced another cause
for heterogeneity among treatment effect and study results.
The number of injections among studies ranged from one to as high as eight in one study12, with
most studies performing between one or two as part of the treatment protocol. There is still no
consensus on the number of injections recommended for PRP treatment.
Five of the studies15,38,39,41,47,54,57,65,66 included in our review received direct sponsorship, or were
provided some form of compensation toward the study or author. Djulbegovic et al.67 examined
the quality of 136 studies evaluating the effectiveness of treatments in multiple myeloma and
found that RCT’s funded solely or in part by industry had a significantly greater effect of new
treatments compared to studies funded by government or non-profit organizations. The reporting
of results for these studies may have biased our analysis and contributed to the overall
heterogeneity of the systematic review.
Finally, 1111,12,37,41,48,51,53,55,59–61 of the included studies had a total sample size equal to or less
than 30. Low sample sizes contribute greatly to the probability of Type II error, where the
variability is still too great to statistically detect a sizable treatment effect and to Type I error
whereby random sampling error captures larger treatment effects than truly exist in the
population.

Conclusions
There is currently no evidence to support the use of ultrasound to guide needle placement when
injecting PRP for resolution of symptoms from palpable tendon or muscle structures in
musculoskeletal pathologies.
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Chapter 4 A Randomized Double-blind Clinical Trial to evaluate
the use of Platelet-rich Plasma versus Corticosteroid Injection in
Plantar Fasciitis
Abstract
Background: Plantar fasciitis is a chronic, degenerative breakdown of the plantar fascia that
spans the sole of the foot. The pathology is associated with point tenderness at the medial side of
the heel and pain and tightness with weight bearing. Corticosteroid (CS) injections is a fairly
common treatment option after other non-operative treatments have failed. Platelet-rich plasma
(PRP) may optimize the healing environment for tissue regeneration and repair such that an
injection of PRP, may provide greater improvements in pain and function than corticosteroid
injections.
Purpose: To compare the pain, function and quality of life in patients who have received a PRP
injection versus a corticosteroid injection for the treatment of plantar fasciitis.
Methods: We conducted a randomized controlled trial (RCT) in patients with plantar fasciitis
who were referred to our clinic from local primary care physicians. Patients were stratified by
symptom duration (less than and greater than three months) and received either a PRP or CS
injection. We measured outcomes at two weeks, six weeks, three months, six months and one
year. Our primary outcome was the AOFAS ankle-hindfoot scale; secondary outcomes included
the SF-12v2® Health Survey and the Plantar Fasciitis Pain and Disability (PFPD) scale.
Results: We screened 159 patients, of which 133 were eligible and randomized (PRP = 66, CS =
67). For the purpose of this thesis we included 114 patients in the analysis (PRP = 57, CS = 57).
At six months the mean and standard deviation of the AOFAS Ankle-hindfoot scale was
67.1±18.3 for the PRP group and 70.8±17.6 for the CS group (mean difference -1.7, CI -7.6 to
4.2, p = 0.6). At one year the mean and standard deviation was 72.3±19.1 for the PRP group and
75.6±17.0 for the CS group (mean difference -1.3 CI -7.3 to 4.6, p = 0.7). We also found no
statistically significant differences between treatment groups for any of the secondary outcome
measures (p > 0.05).
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Conclusion: PRP does not provide greater self-reported pain relief or function than CS
injections in patients with plantar fasciitis.

Introduction
Plantar fasciitis is a chronic, degenerative breakdown of the plantar fascia, most commonly at its
origin of the calcaneus. Injury of the structure is commonly caused by repetitive strain during
locomotion which creates microtears of the fibers, and may include an inflammatory and
associated repair response of the tissue1,2.
Clinical diagnosis of plantar fasciitis includes patient complaint of point tenderness and pain in
the medial plantar heel area of the foot with weight bearing3. The pain is especially severe during
the first few steps in the morning, decreases with rest, and is exacerbated with prolonged weight
bearing activities4,5. Ultrasound imaging has shown a thickening of the plantar fascia on the
involved side by greater than 4mm compared to the uninvolved side in patients who are
symptomatic6.
More than one million individuals present to outpatient clinics with plantar fasciitis each year7.
Approximately 30% of patients with plantar fasciitis will have bilateral pain, and 50% present
with heel spurs which may or may not be symptomatic5,8. Although conservative treatment has
been shown to be successful in 90% of patients, symptoms may last as long as six to 12 months
before relief is attained obtain people afflicted with this disease can expect to have symptoms as
long as six to 12 months5,8,9.
The pathology is most prevalent in patients aged 45-64 years old, and more so in women than
men7. Plantar fasciitis often presents in individuals with increased tensile load on the plantar
fascia, such as running athletes or people with occupations that require prolonged standing. Poor
biomechanics and anatomical variation, such as pes planus (flat feet) and pes cavus (high arches)
are common predisposing factors to plantar fasciitis4,5.
More than 80% of patients find symptom relief with non-operative care1,10 including,
physiotherapy, non-steroidal anti-inflammatory drugs, shoe orthotics or heel pads, night splints,
shockwave therapy, and injections4,5,9. A corticosteroid (CS) injection may also be offered but
usually only after failure of other non-operative treatments.
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Corticosteroid injection is the current standard of treatment for patients who are resistant to acute
treatment (ie. physical therapy). Current literature supports its use for short-term relief of pain.
However, adverse events – including fat pad atrophy and rupture of the plantar fascia – have
been linked to successive corticosteroid injections5,8,11,12.
Li et al13 conducted a systematic review and meta-analysis of studies that evaluated the efficacy
of CS injections compared to a placebo for plantar fasciitis. They included four randomized
controlled trials with a total 289 patients and reported a significant improvement of VAS pain
scores in favour of the CS group at one month (p < 0.05), but no difference was found between
treatments at two or three months post injection (p > 0.05). There was also no difference between
treatments for the improvement of plantar fascia thickness (p > 0.05) on ultrasound evaluation.
Given the adverse event profile of CS, it would be useful to find a safe and effective alternative.
Platelet-rich plasma (PRP) injections have emerged as a promising new treatment that may offer
improved symptom relief compared to CS injections for patients with plantar fasciitis14. PRP is
obtained through the centrifugation of human blood, which results in a high concentration of
platelets suspended in plasma15. Platelets are rich in growth factors essential to the healing
process of tissue. The injection of PRP into injured tissue is theorized to optimize the ideal
healing environment for tissue regeneration and repair16.
Hsiao et al17 conducted a meta-analysis to compare the effectiveness of autologous blood-derived
products (ABP’s) (included PRP treatment), shockwave therapy, and CS injections for the
treatment of plantar fasciitis. They included seven RCT’s and three quasi-experimental studies
for a total of 604 patients. There was no significant differences between the three treatment
groups for VAS pain scores at three and six months post treatment (p > 0.05), but a subgroup
analysis of PRP studies (other ABP’s removed) versus CS treatments at three months revealed a
significant improvement of VAS pain scores in the PRP compared to CS treatments at (p < 0.05).
Finally, Franceschi et al18 conducted a systematic review to evaluate the effectiveness of PRP in
the treatment of plantar fasciopathy. The review included eight studies: three RCT’s, one cohort
study, and four prospective case series. In the first RCT19 comparing PRP (n = 10) to dextrose
prolotherapy (n = 11), they found no significant difference between groups (p > 0.05) at two and
six months for pain, disability, and activity limitation measured using the Foot Functional Index .
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The second RCT20 compared PRP (n = 15) to CS injections (n = 15) using the VAS pain scale
and the Foot Health Status questionnaire at six weeks. The authors reported a statistically
significant difference between treatments for both outcomes (p < 0.05) in favor of PRP. The third
RCT21 also compared PRP (n = 20) to a CS injection (n = 20) at three, six, 12 and 24 months
follow up. The authors found a statistically significant improvement in AOFAS hindfoot scores
in favor of the PRP group at each follow up over the two years patients were followed (p < 0.05).
The prospective cohort study22 compared PRP (n = 30) to CS (n = 30) injection using the VAS
pain scale and the Roles and Maudsley score, a pain and activity limitations scale, at three and
six months follow up. They found no statistically significant difference between groups (p >
0.05). The results of the systematic review suggest promising results for PRP as a treatment for
plantar fasciitis, however, a methodologically rigorous randomized controlled trial with a large
sample size will provide greater certainty about the superiority of PRP.
Therefore, we conducted a RCT in which we compared the effectiveness of PRP versus CS
injections in patients with plantar fasciitis. We hypothesized that PRP may offer a greater
reduction in pain and lead to improved function in patients with plantar fasciitis.

Methods
Study Design
Our study was a RCT that randomized patients to one of two groups (PRP or CS injection) using
a computer-generated 1:1 randomization scheme, in permuted blocks of two and four, with
stratification by duration of symptoms (< six months versus ≥ six months). The investigating
physician, patient, and outcome assessor were all blinded to group allocation. Blood was drawn
from all included patients by the nurse who then prepared and blinded the syringe prior to
injection.

Patient Selection
We recruited patients from surrounding family physician offices using advertising posters
(Appendix 2). Referrals were sent to the office of the investigating physician and patients were
scheduled for a consultation at our sports medicine clinic. The investigating physician diagnosed
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the patient with plantar fasciitis if the patient presented with pain with palpation of the medial
calcaneal insertion of the plantar fascia that was worse in the morning and prolonged weight
bearing, and subsided with rest.
Patients with plantar fasciitis were included if they were between the ages of 18 and 70 years and
were willing to comply with the follow up protocol. Patients were ineligible if they were
diagnosed with a tendon rupture, neurological or vascular insufficiencies in the painful heel,
Paget disease or calcaneal fat pad atrophy, osteomyelitis, fracture of the calcaneus, ankle
inflammation, recent infection in the treatment area, history of rheumatic diseases, collagenosis
or metabolic disorders, immunosuppressive therapy or coagulation disturbance and/or therapy,
long-term treatment with CSs, previous surgery of heel, malignant disease, diabetes mellitus,
severe cardiac or respiratory disease, significant abnormalities in hepatic function.
The study protocol was explained and written consent was obtained. Our study protocol was
approved by our institutional research ethics board and the trial was registered at
clinicaltrials.gov (NCT01614223).

PRP and CS Preparation
All patients were seen at our clinic on Thursday mornings between 8:30am and 1:00pm. Our
nurse (MY) extracted approximately 12cc’s of blood from the patient’s arm, which was then
placed in an Arthrex ACP® double syringe system and spun in a table-top Rotafix 32A
centrifuge at 1500 rpm for five minutes. This process of centrifugation separated the blood into a
visible three-layer consistency of red blood components (bottom), a very thin, milky white
leukocyte component (middle), and yellow plasma components (top). The nurse then extracted
only the plasma from the top layer (between three and 4cc’s) and blinded the syringe using
opaque tape. The remaining fluid was discarded appropriately.
For the CS group, we added 2cc’s of 2% Xylocaine to the 1cc solution of Celestone to
equilibrate the weight with the PRP treatment to maintain blinding of the investigating physician.
The CS solution was prepared in an opaquely blinded syringe identical to the size of the smaller
syringe used in the Arthrex ACP® double syringe system.
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Injection Method
We used the same method of injection for both the ACP® and CS treatments. The investigating
physician (KW) palpated the point of most tenderness and marked the spot. The plantar surface
and heel of the involved foot was then sterilized and prepped for injection. A local analgesic,
Lidocaine (2% concentration) was injected superficially into the area. This was followed
immediately by the ACP® or CS injection into the marked spot. If patients indicated that they
had excessive pain three months after the first injection, we offered a second injection of the
group allocated treatment.

Outcome Measures and Follow Up
Our primary outcome measure was the American orthopaedic foot and ankle society (AOFAS)
scale. The AOFAS scale is a validated and reliable region-specific, quality of life and objective
functional scale23–25. It is a combination of a patient-reported grading of pain, functional ability
during activities of daily living, and physician assessed range of motion (ROM), stability, and
ankle alignment. The scale is scored as an overall total out of 100, where a score of 100
represents the best possible outcome.
Secondary outcome measures included the Plantar Fasciitis Pain and Disability (PFPD) scale and
the SF-12v2® Health Survey. The PFPD is a disease-specific pain and disability scale that has
shown comparative validity and reliability with the Foot Function Index (FFI) and the visual
analogue pain scale (VAS)26,27. The SF-12v2® is a well-known generic quality of life scale28.

Sample Size Calculation
Based on the ability to detect a moderate effect size of 0.5 with 80% statistical power and 0.05
type one error, we calculated a sample size of 64 patients per group. To account for a drop-out
rate of 10% we recruited a final sample size of 70 patients per treatment group.

Statistical Analysis
We followed the intention-to-treat (ITT) principle. We calculated the adjusted mean, adjusted
between-group mean difference with 95% confidence interval, and associated probability values.
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We used an analysis of covariance (ANCOVA) to analyze the primary outcome where the
dependent variable was the AOFAS score at six months and one year post-treatment, the
independent variable was the treatment group and the covariate was the baseline AOFAS score.
We used the same analysis for the secondary outcomes. For patients with missing data points
between visits we used regression to impute missing values. We included the last outcome
carried forward (LOCF) in the analysis for patients who were lost to follow up. We determined
the minimal clinically important difference (MCID) for all outcome measures as a between
group difference of 20%29. We calculated a within-groups MCID by calculating the pooled
standard deviation (SD) of the treatment groups at baseline, multiplied this value by a moderate
effect size of 0.5. We then converted this value into a between-groups MCID by multiplying the
within-groups MCID by 0.2 as described by Goldsmith et al29.

Results
For the purpose of this thesis paper, we analyzed the data of patients who were at least 1 year
post intervention (n=114). Between 2010 and 2015, 159 patients were screened for eligibility. Of
these, 24 were ineligible: 11 did not have plantar fasciitis, eight did not want to be randomized,
four had a concomitant disease, and one received a steroid injection two weeks prior to the
baseline visit. Therefore a total of 133 patients were eligible, gave consent, and were randomized
into treatment groups (Fig. 7).
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Patients screened
n = 159

Patients ineligible
n = 24

Patients
randomized
n = 133
Included in this
thesis
n = 114
ACP® injection
group
n =57

CS injection group
n = 57

6 month follow up
n = 57
(Missed n = 7)

6 month follow up
n = 57
(Missed n = 6)

1 year follow up
n = 57
(Missed n = 4)

1 year follow up
n = 57
(Missed n = 2)

Figure 7 Study patient flow diagram of treatment groups.
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Treatment groups were balanced for baseline demographics (Table 8). Independent groups t tests
showed no statistically significant differences between treatment groups for baseline scores of
the AOFAS ankle-hindfoot scale, SF12, and PFPD questionnaire (Table 9 and Fig. 8).
Demographic
Age (years)
Height (cm)
Weight (kg)
Sex (% Male)
Symptom duration (months)
Affected side:
Right
Left
Both
Foot alignment
Cavus
Planus
Neutral
Smoker
Previous treatments:
Physical therapy
Orthoses:
Over the counter
Custom
Taping or heel pads
Shoe modification
Night splints
Topical analgesic or NSAIDs
Prescription analgesics or NSAIDs
Local anaesthetic injection
Electrocorporeal shockwave therapy
Corticosteroids
Other (acupuncture, cast, massage,
weight loss, laser therapy)

ACP® Group
n = 57

CS Group
n = 57

52 ± 11
168 ± 12
88 ± 18
25 (44%)
37 ± 62

48 ± 9
168 ± 14
84 ± 18
19 (33%)
32 ± 63

20 (35%)
32 (56%)
5 (9%)

29 (51%)
26 (46%)
2 (4%)

9 (16%)
6 (11%)
42 (74%)
16 (28%)

8 (14%)
11 (19%)
38 (67%)
16 (28%)

36 (63%)
42 (74%)
5 (9%)
37 (65%)
20 (35%)
7 (12%)
13 (23%)
9 (16%)
9 (16%)
2 (4%)
8 (14%)
13 (23%)
0

36 (63%)
40 (70%)
4 (7%)
36 (63%)
18 (32%)
12 (21%)
19 (33%)
11 (19%)
19 (33%)
3 (5%)
9 (16%)
17 (30%)
9 (16%)

Table 8 Pre-intervention demographics for randomized patients. Values represent the mean
± standard deviation for variables measured using a continuous scale and the number and
proportion for variables measured using a dichotomous scale.
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Primary outcome
4.4.1.1 AOFAS
We found no statistically significant difference between treatment groups for improvement in
pain and function for the AOFAS Ankle-hindfoot scale at six months or one year follow up. The
adjusted mean differences were -1.7 (CI -7.6 to 4.1, p = 0.57) at six months and -1.3 (CI -7.3 to
4.6, p = 0.66) at one year.
AOFAS
Baseline
2 weeks
6 weeks
3 months
6 months
1 Year
PFPD
Baseline
2 Weeks
6 Weeks
3 Months
6 Months
1 Year
SF12 PCS
Baseline
2 Weeks
6 Weeks
3 Months
6 Months
1 Year
SF12 MCS
Baseline
2 Weeks
6 Weeks
3 Months
6 Months
1 Year

ACP®

CS

MD (95% CI)

p value

53.5±2.6
60.9±1.7
64.4±2.0
65.1±1.9
68.1±2.1
73.3±2.1

57.8 ± 2.6
64.3±1.7
64.3±2.0
67.1±1.9
69.8±2.1
74.6±2.1

-4.3 (-11.4 to 2.9)
-3.4 (-8.1 to 1.4)
0.1 (-5.5 to 5.7)
-2.0 (-7.4 to 3.3)
-1.7 (-7.6 to 4.1)
-1.3 (-7.3 to 4.6)

0.24
0.16
0.96
0.46
0.57
0.66

63.4±1.6
54.2±1.7
49.0±2.2
46.8±2.3
41.4±2.8
33.5±2.6

60.1±1.6
50.5±1.7
47.8±2.2
45.8±2.3
42.1±2.8
36.3±2.6

3.3 (-1.2 to 7.8)
3.8 (-0.9 to 8.5)
1.2 (-4.9 to 7.3)
0.9 (-5.5 to 7.3)
-0.7 (-8.7 to 7.2)
-2.8 (-10.1 to 4.5)

0.15
0.12
0.70
0.78
0.86
0.45

40.8±1.3
42.7±0.8
42.8±0.9
43.9±1.0
44.5±1.1
46.9±1.1

42.1±1.3
44.3±0.8
44.2±0.9
44.3±1.0
45.3±1.1
46.7±1.1

-1.4 (-4.9 to 2.2)
-1.7 (-3.9 to 0.6)
1.3 (-3.9 to 1.2)
-0.5 (-3.4 to 2.5)
-0.8 (-3.8 to 2.2)
0.2 (-2.9 to 3.2)

0.44
0.15
0.29
0.76
0.61
0.91

48.9±1.6
49.9±0.9
50.4±1.0
50.1±1.0
51.7±1.1
52.3±1.1

49.6±1.6
48.6±0.9
49.5±1.0
49.9±1.0
50.5±1.1
51.4±1.1

-0.7 (-5.3 to 3.9)
1.3 (-1.1 to 3.7)
0.9 (-1.9 to 3.8)
0.2 (-2.8 to 3.1)
1.2 (-1.8 to 4.2)
0.9 (-2.2 to 4.1)

0.76
0.27
0.51
0.92
0.43
0.57

Table 9 AOFAS Ankle-hindfoot scale, Plantar Fasciitis Pain and Disability scale (PFPD),
and SF12 Physical and Mental Component Summary (PCS and MCS) adjusted scores
(mean ± standard error). Negative values are in favour of CS injections. MD = mean differ.
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AOFAS score by group over time
100
90
80
70

Score

60
50
40
30
20
10
0
B

2wk

6wk

3m

6m

1yr

Time
PRP

Corticosteroid

ACP®

Figure 8 Unadjusted means and confidence intervals (error bars) for the AOFAS outcome
measure over time. B = baseline, wk = week, m = month, yr = year

Secondary outcomes
4.4.2.1 Plantar Fasciitis Pain and Disability (PFPD)
We found no statistically significant difference between treatment groups for the disease-specific
PFPD scale at six months or one year. The adjusted mean differences were -0.73 (CI -8.68 to
7.22, p = 0.86) at six months and -2.78 (CI -10.1 to 4.54, p = 0.45) at one year.

4.4.2.2 SF12 Physical Component
We found no statistically significant difference between treatment groups for the physical
component score of the SF12 at six months or one year. The adjusted mean differences were -0.8
(CI -3.8 to 2.2, p = 0.61) at six months and 0.2 (CI -2.9 to 3.2, p = 0.91) at one year.
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4.4.2.3 SF12 Mental Component
We found no statistically significant difference between treatment groups for the mental
component score of the SF12 quality of life outcome measure at six months or one year. The
adjusted mean differences were 1.2 (CI -1.82 to 4.22, p = 0.43) at six months and 0.92 (CI -2.24
to 4.08, p = 0.57) at one year

Adverse Events and Second Injection
Three patients in the ACP® group each received a second injection at three, six, and 12 months
respectively. Two patients in the CS group received a second injection at six months. One patient
in the CS group and one patient in the PRP had complete pain relief in the affected limb and
requested the same injection on the contralateral foot. One patient in the CS group and three
patients in the ACP® group had unresolved pain at the end of the study. One patient in the CS
group ruptured their plantar fascia six months after completing the study.

Discussion
Chronic plantar heel pain is a debilitating condition that has a significant negative impact on both
foot-specific and general health-related quality of life30. For patients who find no relief from
non-operative care, injection therapy of steroids or autologous blood products may offer some
relief of symptoms and promote healing3,4,31. In our study we found no statistically significant
difference between injections of CS or PRP in the amount of improvement in self-reported pain
and function as measured by the AOFAS Ankle-hindfoot scale in patients with plantar fasciitis.
Secondary outcomes were also not significantly different between treatment groups.
The 95% confidence intervals around the mean difference for each outcome do not rule out the
possibility that PRP is superior to CS. However, we can be certain that if there is a benefit of
PRP, the difference not likely to be large and therefore is not likely to justify the cost.
On the other hand, CS injections in patients struggling with plantar fasciitis have not shown long
term superior effectiveness compared to placebos13 and repeated use of CS in tendons has been
associated with adverse effects such as plantar fascia rupture and/or fat pad atrophy32–34. In our
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study, one patient in the CS group had a rupture of their plantar fascia six months after their one
year follow up. Thus, if PRP can offer similar benefits to CS without the added risk of tendon
degeneration, it may offer a reasonable alternative to an injection of CS.
PRP is theorized to create an environment essential for healing tissue through the release of
growth factors from platelets when the cells become activated during clotting. The collective
body of literature evaluating the effectiveness of PRP compared to CS injections for patients
with plantar fasciitis contains a range of different preparation systems with individualized
preparation methods used to create the PRP35–37. This results in varying concentrations of
platelets and may obscure the overall treatment effect. Additionally, there is a lack of welldesigned RCT’s with standardized outcomes and long term follow ups to support the conclusive
evidence of the comparison between PRP and CS injections for plantar fasciitis.
In the network meta-analysis by Franceshi et al18 that compared PRP versus other injections in
patients with plantar fasciitis, authors included three RCT studies, and three comparative cohort
studies. The total number of participants included in each study ranged from 30 to 61 patients
whereas our study included almost double (n = 114) the number of patients compared to the
study with the most participants. Two of the included studies were single-blind and the rest did
not use blinding whereas we were able to blind the patient, physician, and outcomes assessor to
group allocation. The maximum follow up period with the included studies was six months postinjection, whereas our study followed patients up to one year after treatment. For these reasons,
we are confident that our conclusions represent the most rigorous findings to date.
Another recently published study38 comparing the effectiveness of PRP (n = 25) versus CS (n =
25) injections in patients with plantar fasciitis, compared treatment groups at six weeks and six
months using the VAS pain scale and the AOFAS scale. Authors found a statistically significant
difference between groups for all outcomes at both follow up periods (p < 0.05) in favour of
PRP. In evaluating the internal validity of the study, patients chose which treatment they
preferred and were then allocated into groups accordingly. Although the groups were balanced
for baseline demographics, the omission of randomization may have introduced a selection bias
and influenced the results.

71

Shetty et al39 also published the preliminary results of a non-randomized trial where authors
compared PRP (n = 30) versus CS (n = 30) injections in patients with plantar fasciitis. The
groups were compared at three months after the injection using the VAS pain scale, the Foot and
Ankle Disability Index (FADI), and the AFAS. The authors found a statistically significant
improvement of scores in favor of PRP for all outcomes at three months (p < 0.05). The process
of group allocation was not described and no method of blinding was implemented.

Study Limitations
In our study, patients were allowed to add other forms of non-operative management (e.g.
orthotics, laser therapy, massage, physiotherapy, etc.) for plantar fasciitis to their treatment
regimen, with the exception of injections which made our study more pragmatic and applicable
to regular practice where patients seek a variety of treatment options for plantar fasciitis.
However, we did record the number of patients who sought physiotherapy during the study
treatment period and found that they were balanced between groups (ACP® = 23, CS = 25).
The study was performed at a single-centre with a single surgeon performing all injections.
Although the surgeon is a fellowship-trained physician with many years of experience, the
addition of other centres and physicians may have added to the generalizability of the results.
We did not perform any ultrasound diagnostic evaluation of the plantar fascia to compare the
thickness before and after treatment. Plantar fasciitis is known to be associated with a thickening
of the plantar fascia40, and evaluation of the improvement of the thickness between treatment
groups may have been a useful tool.
We did not have a placebo group in our study, which limited our ability to make inferences about
its superiority to no treatment at all. However, since we were trying to determine whether ACP
could replace CS as a treatment for plantar fasciitis (given its adverse event profile), if we could
show that ACP was similar or superior to corticosteroids then it is not necessary to compare ACP
to placebo.
Individual variations of platelet concentration may have different effects on treatment
outcomes43. Although we did not evaluate the concentration of platelets achieved for each
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injection, other studies44 conducted by this same group demonstrated consistent concentrations
between two and three times greater than baseline blood which has been shown to be
effective41,42.
Despite meeting our a priori sample size requirements, our confidence intervals were too wide to
allow definitive conclusions about the superiority of ACP® compared to CS). However, we can
be certain that if there is a benefit of ACP® over CS that the effect is small; thus it is reasonable
to adopt ACP® as part of usual treatment option prior to administration of CS43. The only other
consideration is the cost to the patient and whether it is covered by public or third-party funding.
PRP preparation systems produce either leukocyte-rich (LR) or leukocyte-poor (LP) PRP.
Leukocytes contain and produce cytokines which promote catabolic (molecular breakdown)
cellular activity and inflammation44 which is counteractive to the anabolic actions of the growth
factors released by platelets in PRP. Thus, one expects that reduced leukocyte levels within a
PRP solution may have a more positive effect on healing than leukocyte-rich PRP44,45. The
presence or absence of inflammation in the damaged tissue is influential to the process of
healing46. In acute pathologies where initial inflammatory activity is occurring at the site of
tissue damage, additional leukocyte promotion may not be beneficial. However, in chronic
conditions where the inflammatory process has subsided or no longer occurs, the addition of
leukocytes may be advantageous in stimulating the initial healing process47. Plantar fasciitis has
recently been redefined to classify the condition as plantar fasciosis when the symptoms are
chronic without inflammation2. The absence of inflammation in the damaged tissue causes the
healing response to include less inflammatory cellular activity than in an acute condition. For
this reason, the ideal PRP solution for plantar fasciitis, given that it is a chronic condition, may
need to include leukocytes to stimulate the necessary inflammatory response for healing to take
place48. The ACP® solution used in our study did not contain leukocytes.

Future Directions
Directions for future research into the effectiveness of PRP injections in patients with plantar
fasciitis should include a standardized physiotherapy, and the use of a PRP treatment that
includes leukocytes. Plantar fasciitis is a chronic condition that is not always associated with
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inflammation2 and the presence of leukocytes which is known to promote inflammation may
work in favor of creating the natural healing environment for the fascia.

Conclusion
We found no evidence thatACP is inferior to CS in patients with plantar fasciitisGiven the
adverse event profile of CS it is reasonable for clinicians to use ACP prior to CS.
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Chapter 5 Summary

With an ever ageing population more active later in life, there is a demand for sports pathology
treatment regimens that can both treat clinical symptoms and provide healing to the injured tissue
for a continued active lifestyle. An injection of platelet-rich plasma (PRP) into injured tissue is
theorized to provide an ideal healing environment through the introduction of growth factors
imperative to tissue regeneration1,2. With improved tissue regeneration and enhanced overall
healing of the pathology, patients should experience reduced pain, and improved function and
quality of life. Over the last decade there have been a number of studies evaluating the
effectiveness of PRP for sports medicine pathologies, however the variation in types of
pathology, treatment methods, and PRP-specific treatment protocols have clouded the clarity in
treatment effect.
Chapter 2: In our systematized review of the literature to evaluate the effectiveness of PRP in
various tissue-specific pathologies, we found no definitive clinical evidence to support the use of
PRP. For tendon healing, half of the studies found a significant treatment effect in favor of PRP
while the other half found no difference. In the two studies we evaluated for the use of PRP in
bone healing, the studies were again split with one finding a statistically significant effect in
favor of PRP and the other finding no difference. Again, in muscle healing the two studies we
evaluated were also split with one finding a significant difference in favor of PRP and the other
finding no difference. The use of PRP in intra-articular injections of the knee did show some
encouraging results, particularly in the treatment of osteoarthritis of the knee. We speculate that
this may be because the PRP provides growth factors in an environment where the damaged cells
are no longer able to maintain cell reparation through their own growth factor releasing
mechanism3–5.
Chapter 3: One area of dispute in the application of PRP injection is whether or not injections
should be administered using ultrasound to guide needle placement. Proponents of PRP have
argued that unless the investigator has taken measures to ensure that the PRP was administered
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to the correct location, that conclusions about effectiveness (especially lack of effectiveness) are
no more than speculative. To address this controversy, our second systematic review compared
the effectiveness of PRP in ultrasound versus palpation guided injections for the non-operative
treatment of tendon and muscle pathologies. We found no published studies directly comparing
ultrasound versus palpation guided injections of PRP, which meant that we used an indirect
analysis to make the comparison. We found no statistically significant differences between
treatment methods for failure rates or pain scores at less than two months, two to three months,
and six months post-injection. We did find a statistically significant difference in favor of
palpation guided injections for functional scores at six months post-injection, but the
heterogeneity of the comparison was high and so definitive superiority could not be concluded.
Therefore, we found no evidence to support the claim that ultrasound guided injections of PRP
offer greater outcomes and the additional cost and inaccessibility of the ultrasound equipment in
the clinic setting work against its adoption into practice.
Finally, given the lack of high powered studies and unstandardized PRP preparation methods we
set out to complete a methodologically rigorous RCT to compare the effectiveness of PRP
injections compared to corticosteroid (CS) injections in patients with plantar fasciitis.
Chapter 4: Our study was a computer generated RCT where the patients, the physician
administering the injection, and the outcomes assessor were blinded. We used the American
Orthopaedic Foot and Ankle Society (AOFAS) ankle-hindfoot scale, the SF-12v2® Health
Survey, and the Plantar Fasciitis Pain and Disability scale, all valid and reliable patient-reported
outcome measures. We had a long term follow up of one year, with interval assessments at two
weeks, six weeks, three months, and six months after the injection. We had a large sample size of
114 patients with only a 7% drop out rate. Following our intention-to-treat analysis, we found no
statistically significant difference for our primary outcome (AOFAS) at six months or one year
post-injection. In addition, we found no significant difference for any of our secondary outcomes
at six months or one year. However, confidence intervals around the estimates of effect were
large and could not rule out the possibility of a beneficial effect of PRP over CS. Our results do
suggest however, that it is most likely that PRP injection provides similar pain relief and
functional improvement compared to CS but without the serious side effects observed with CS;
like tendon rupture which may justify its use.
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Regulation of PRP Applications
In the United States, PRP is regulated by the Food and Drug Administration (FDA) and is
classified as a Biologic under the Center for Biologics Evaluation and Research (CBER)6.
Products in this class apply for approval using the 501 (k) application process that allows devices
that are similar to other already approved devices to be introduced onto the market. The PRP
preparation systems fall under this category and for this reason the available systems are both
numerous and vary considerably in the way they are used and in the resulting components of the
PRP product.
Originally, PRP systems were approved by the FDA for use in the mixing of the PRP product
with bone graft materials for orthopaedic surgical use. The transfer of PRP into the clinical
setting as an injectable treatment, termed “off label”, has become acceptable in North America
with the understanding that clinicians will use the treatment with self-determined ethical and
evidential discretion to do no harm. However, controversy has arisen in the use of PRP that uses
an activator such as thrombin and/or calcium to activate the clotting mechanism during the
application of PRP7 because this would be in addition to the treatment as initially approved. The
activator changes the cellular composition of platelets and therefore produces a manipulation of
the end product.
The conflict in the regulation of PRP systems has a direct effect on the quality of research and
resulting evidence to support its use in clinical practice. Since the products approved under the
501 (k) application do not require evidence from laboratory, animal, and clinical studies, the
current body of research has not undergone the stringent methodology controls and scrutiny as
products classified as drugs. The research in the effectiveness of PRP has increased
tremendously over the past decade, but the validity and reliability of the evidence is
questionable.

Directions for future studies
The true measure of efficacy for the use of PRP in musculoskeletal pathologies has been diluted
by the variation in methodology used in the published literature. Future studies evaluating the

83

effectiveness of PRP needs to adhere to certain standardized protocols to be included in a pooled
collection of results that will provide the necessary evidence to change clinical practice.

Choosing a PRP preparation system
All PRP products are not equal, and comparison of the treatments produced by different systems
should be considered thoroughly before comparing their effectiveness. For example, when we
compare two studies with the same pathology and study design, but using different PRP
preparation systems, one study may produce non-significant results while the other finds a
statistically significant effect of PRP. This may have been the case in a comparison of our plantar
fasciitis RCT where we found no significant difference between PRP and corticosteroid
injections, versus Shetty et al8 in which the authors found a statistically significant difference in
favor of PRP for similar patient-reported functional outcomes when they also compared PRP to
corticosteroid injections in patients with plantar fasciitis. In our study we used the ACP Double
Syringe, Arthrex system which produced a concentration of two to three times higher than
baseline blood. The other study used the SmartPrep, Harvest Technologies system which is
known to produce platelet concentrations four to six times greater than baseline levels, and the
protocol also requires the addition of an anti-coagulant and activator be added. Researchers need
to focus their efforts on finding the most effective PRP solution for cell types that are important
in healing the effected structure (e.g. tenocytes, myocytes, chondrocytes, osteocytes), followed
by measuring the effect of that preparation in a specific tissue type (e.g. tendon, muscle,
cartilage, bone), and finally, exploring the effectiveness for treating musculoskeletal pathologies
within a specific patient population.

Acute versus chronic conditions
Tiwari et al9 describes four different types of PRP treatments: leukocyte-poor or pure PRP,
leukocyte PRP, pure platelet-rich fibrin clot, and leukocyte platelet-rich fibrin clot. All of these
fall under the collective PRP treatment umbrella, however the solution content, concentration,
and consistency vary considerably. For musculoskeletal pathologies, the healing of tissue is
highly dependent on the stage of healing and the body’s natural response of cellular activity and
differentiation in the area of injury. Acute pathologies are associated with an inflammatory

84

response, whereas chronic conditions are associated with reduced inflammation or the absence of
inflammation in the area. Since leukocytes are known to cause an inflammatory response in the
local tissue, and the inclusion or removal of the cells may have a direct effect on the healing
response of the injured tissue. Therefore, we suggest that investigators consider the stage of
healing when selecting the type of PRP to treat that particular pathology.
The fibrin clot is used in the surgical application of PRP. During a surgical procedure the injured
tissue is repaired and the area begins the acute phases of healing. The PRP solution applied here
should also be one that should complement the acute healing phase which already includes an
inflammatory response and may be adversely affected by the addition of leukocytes.

Requirements for future studies
Future research studies evaluating the effectiveness of PRP should include greater detail in the
PRP preparation method and treatment protocol. This is necessary for the fair comparison across
studies and valid pooling of data in meta-analyses. The PRP preparation system used, the
inclusion or exclusion of leukocytes, and the use of anticoagulants and/or activators should be
specified. The use of image-guidance for injection and a detailed description of how the
treatment was applied should also be described.

Conclusion
The use of PRP treatments in musculoskeletal pathologies is a promising biological addition that
should be further explored in clinical trials with higher levels of evidence. Researchers and
clinicians should consider various aspects of PRP treatment and the options available that will
produce the most successful treatment for patients in the clinical setting.
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